The bone marrow of 22 untreated children with acue lymphocytic leukemia were examined cytochemically with periodic acidSchiff (PAS) reaction. PAS positivity was correlated with relapse rate and duration of complete remission. 18 months after achieving remission 10 of 12 patients with strong PAS-positive marrow at the time of diagnosis are still in complete remission in contrast to only 3 of 10 patients with weak PAS-positive marrow. Of the 10 patients with weak PAS positivity one did not achieve remission, five developed complete (central nervous system, CNS, and hematologic) relapse and one relapsed in the CNS. Of the 12 patients with strong PAS-positive initial marrow, 10 remain in complete continuous remission, one had hematologic relapse and one developed meningeal leukemia. From these data we conclude that PAS positivity is directly related to the duration of initial remission in children with acute lymphocytic leukemia.

Keywords:
Acute lymphocytic leukemia, Childhood leukemia, Cytochemistry, Leukemia relapse rate, PAS reaction
This content is only available via PDF.
© 1974 S. Karger AG, Basel
1974
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.